TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04896086
Drug: VRC-GENADJ0110-AP-NV (Adjuplex)
Normalized name: AP
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuplex is a sterile, pyrogen-free adjuvant solution produced by the VRC Pilot Plant. Adjuplex comprises highly purified de-oiled soy lecithin and benzene-free carbomer homopolymer formulated in phosphate buffered saline. Adjuplex adjuvant was mixed with FluMos-v1 at 20% by volume in the pharmacy during product preparation for the vaccinations of Groups 5A-5B.
Study: NCT04896086
Drug: VRC-FLUMOS0111-00-VP (FluMos-v1)
Normalized name: VP-14637
DrugBank: VP-14637 (DB12195)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FluMos-v1 investigational vaccine is composed of engineered pentameric promoters based on C. albicans lumazine synthase assembled with 20 trimeric promoters displaying HA ectodomains. It contains hemagglutinin (HA) proteins from the following 4 influenza strains: A/Idaho/07/2018, A/Perth/1008/2019, B/Colorado/06/2017 and B/Phuket/3073/2013.
Study: NCT05724134
Drug: Insulin human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin infusion rate (IIR) will be determined empirically first to maintain mean basal fasting plasma glucose, and then either maintained at the basal rate (MH protocol) or be reduced stepwise toward euinsulinemia (RE protocol).
Study: NCT05724134
Drug: Octreotide Acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Octreotide will be infused at 30 ng/kg/min to suppress endogenous insulin, glucagon, and growth hormone secretion. Co-administered with glucagon and rhGH.
Study: NCT05724134
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon will be replaced at a constant rate of up to 0.65 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and rhGH.
Study: NCT05724134
Drug: 20% D-glucose (aq)
DrugBank: D-glucose (DB01914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% D-glucose (aq) (D20W) will be administered to counteract hypoglycemia or strongly downward blood glucose trends, as needed.
Study: NCT06599775
Drug: Adebrelimab injection
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group：Adebrelimab is an innovative PD-L1 inhibitor, monotherapy can improve pathological complete response rates with tolerable safety
Study: NCT06599775
Drug: Albumin-Bound Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Experimental group：combined with Adebrelimab（PD-L1 inhibitor）,and carboplatin followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
Study: NCT06599775
Drug: Carboplatin injection
Normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Experimental group：combined with Adebrelimab（PD-L1 inhibitor），and albumin-bound paclitaxel followed by endoscopic resection and subsequent simultaneous radiotherapy combined with albumin-bound paclitaxel and carboplatin
Study: NCT04808505
Drug: Miglustat
Normalized name: Miglustat
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 65 mg oral capsules
Study: NCT05809271
Drug: MDMA 120 mg + MDMA 60 mg
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of 120 mg racemic MDMA will be administered followed by a second dose of 60 mg racemic MDMA two hours later.
Study: NCT06744504
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cytarabine combined with daunorubicin was used for induction therapy. According to the different doses of cytarabine, it was divided into standard dose group and intermediate dose group.In addition, high doses of cytarabine are also used for post-remission treatment.
Study: NCT06744504
Drug: daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: combined with cytarabine and used for induction therapy
Study: NCT06744504
Drug: idarubicin
Normalized name: Idarubicin
DrugBank: Idarubicin (DB01177)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: combined with cytarabine and cyclophosphamide and used for post-remission treatment
Study: NCT05175352
Drug: Cendakimab
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06744777
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin is an antiviral medication administered as part of the intervention arm. It will be provided orally in a dosage of 15 mg/kg body weight twice daily (BD) for a duration of 7 days. The drug has demonstrated efficacy in vitro and in vivo against RNA viruses, including dengue, through mechanisms such as inosine monophosphate inhibition and immunomodulation.
Study: NCT05685537
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of levosimendan 48 hours before surgery
Study: NCT06745154
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given nicotine patches, gum, or lozenges
Study: NCT06056895
Drug: Tuparstobart
Normalized name: Tuparstobart
DrugBank: Tuparstobart (DB19118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06056895
Drug: Verzistobart
Normalized name: Verzistobart
DrugBank: Verzistobart (DB18895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05030831
Drug: INZ-701
Normalized name: INZ-701
DrugBank: INZ-701 (DB17629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INZ-701 is a recombinant fusion protein that contains the extracellular domains of human ENPP1 coupled with an Fc fragment from an immunoglobulin gamma-1 (IgG1) antibody (rhENPP1-Fc).
Study: NCT05142722
Drug: Obicetrapib
Normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg obicetrapib tablet
Study: NCT04468776
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolpidem, as prescribed by physician
Study: NCT04468776
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone, as prescribed by physician
Study: NCT05687903
Drug: TAK-861
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-861 oral tablets
Study: NCT04634578
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.~Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution.
Study: NCT05338086
Drug: MB09 (denosumab biosimilar)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pre-filled syringe (PFS) 60 mg/mL solution, administered as subcutaneous injection
Study: NCT05338086
Drug: EU-Prolia
Normalized name: Prolia
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PFS 60 mg/mL solution, administered as subcutaneous injection
Study: NCT06705127
Drug: TORIPALIMAB INJECTION(JS001 )
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles.
Study: NCT04731467
Drug: CM-24 and Nivolumab - Dose Escalation
Normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose escalation of CM24 with nivolumab in adult patients with selected recurrent or metastatic solid tumors
Study: NCT04731467
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
Study: NCT04731467
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
Study: NCT06704893
Drug: Normal saline injection group
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of sterile normal saline.
Study: NCT04731467
Drug: Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
Study: NCT04731467
Drug: Nivolumab and Nal-IRI/5-FU/LV - Expansion
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
Study: NCT06275919
Drug: Regorafenib 40 MG Oral Tablet
Normalized name: regorafenib 40 MG Oral Tablet
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Study: NCT04856293
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 250 mg crizotinib dose of the FC formulation
Study: NCT04856293
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
Study: NCT04856293
Drug: Crizotinib
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
Study: NCT06706713
Drug: BEBT-109 Capsule
Normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
Study: NCT06704828
Drug: SHR-4602
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-4602
Study: NCT06244082
Drug: AOC 1044
Normalized name: AOC 1001
DrugBank: AOC 1001 (DB18620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AOC 1044 will be administered via intravenous (IV) infusion
Study: NCT03775174
Drug: Mepsevii
Normalized name: Mepsevii
DrugBank: Vestronidase alfa (DB12366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04188665
Drug: MASL
Normalized name: MENTHOL 1.25 g in 100 g / CAMPHOR (NATURAL) 5 g in 100 g / METHYL SALICYLATE 10 g in 100 g TOPICAL OINTMENT [Manteca Maslac]
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with MASL lozenge
Study: NCT06706414
Drug: Denosumab (Prolia)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection with 60 mg Denosumab once
Study: NCT04840199
Drug: Letermovir Oral Tablet
Normalized name: letermovir Oral Tablet
DrugBank: Letermovir (DB12070)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 480 mg administered orally once daily with or without food
Study: NCT06103266
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
Study: NCT04990349
Drug: Oxygen gas
Normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
Study: NCT04159597
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Upadacitinib will be administered as oral solution.
Study: NCT05556616
Drug: Modakafusp alfa
Normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modakafusp alfa intravenous infusion.
Study: NCT05556616
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide capsules orally.
Study: NCT05556616
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib injection subcutaneously.
Study: NCT05556616
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib intravenous infusion.
Study: NCT05556616
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab injection subcutaneously.
Study: NCT05556616
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide capsules orally.
Study: NCT06342713
Drug: BGB-45035
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04715867
Drug: Rabix-VC
Normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
Study: NCT04989699
Drug: Aflibercept/Sham
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept administered every 8 weeks
Study: NCT06705322
Drug: Cnidium Monnieri Detoxification Formula
Normalized name: Cnidium monnieri fruit oil
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug composition of Cnidium Monnieri Detoxification Formula: snake seed 9g, Tuckaia 30g, Matrine 9g, snake berry 30g, white Ying 30g. Based on the Cnidium Monnieri Detoxification Formula, the other symptoms were treated with syndrome differentiation and flavor. The traditional Chinese medicine decoction is provided by the Pharmacy of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, with 1 dose per day, decocted into 300ml by a medicine decocter, packed in 2 vacuum bags, taken orally after meals, twice a day, one bag each time. Do not stop taking decoction during menstruation. 1 month is a course of treatment, at least 3 courses of treatment, no more than 6 courses of treatment.~Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment.
Study: NCT06704581
Drug: 10 mg BGM0504 injection administered subcutaneously (SC) once a week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg BGM0504 injection administered subcutaneously (SC) once a week.
Study: NCT05283226
Drug: NRC-2694-A
Normalized name: NRC-AN-019
DrugBank: NRC-AN-019 (DB17110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg orally once daily
Study: NCT05283226
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m² IV infusion over approximately 3 hours
Study: NCT06056596
Drug: Lamivudine 300 MG
Normalized name: lamivudine 300 MG
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
Study: NCT06472583
Drug: Keytruda
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)
Study: NCT05594758
Drug: Olverembatinib
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Olverembatinib
Study: NCT06279351
Drug: Thalidomide+cetuximab+FOLFOX/FOLFIRI
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Thalidomide+cetuximab+FOLFOX/FOLFIRI
Study: NCT05687851
Drug: Cadonilimab（AK104）
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: q3w iv
Study: NCT04874025
Drug: Ibrance
Normalized name: Ibrance
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observational study of Ibrance 75 mg, 100 mg and 125 mg.
Study: NCT05954962
Drug: Progesterone 200 MG
Normalized name: progesterone 200 MG
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation.
Study: NCT05954962
Drug: Ganirelix Acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
Study: NCT04984837
Drug: Lacutamab
Normalized name: Lacutamab
DrugBank: Lacutamab (DB15322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/IV
Study: NCT04984837
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m²
Study: NCT04984837
Drug: Oxaliplatine
Normalized name: oxaliplatine
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m²
Study: NCT05274243
Drug: 2-HOBA
Normalized name: 2-HOBA
DrugBank: 2-(aminomethyl)phenol (DB14855)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-HOBA acetate (2-Hydroxybenzlamine acetate) 750mg (provided as three 250mg capsules) three times per day for 4 weeks
Study: NCT06507306
Drug: osimertinib
Normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral osimertinib
Study: NCT06290102
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Study: NCT06160531
Drug: CC-42344
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-influenza A agent
Study: NCT06036745
Drug: Pembrolizumab + SOX
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
Study: NCT04884009
Drug: SHR-1701； Famitinib
DrugBank: Famitinib (DB11741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1701+ Famitinib
Study: NCT04884009
Drug: SHR-1701
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1701
Study: NCT06001047
Drug: Group B
Normalized name: Blood group B IgM
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol.
Study: NCT06390059
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.~Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Study: NCT06390059
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.~Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Study: NCT06390059
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.~Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Study: NCT04895579
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab will be delivered at 10mg/kg via IV infusion at days 1 and 15 every 28 days or 1500 mg on D1, q4w.